[ad_1]
Equities researchers at Roth Capital started coverage on shares of Intec Pharma (NASDAQ:NTEC) in a note issued to investors on Friday, October 5th, The Fly reports. The firm set a “buy” rating and a $8.50 price target on the biotechnology company’s stock. Roth Capital’s target price points to a potential upside of 53.15% from the company’s current price.
Several other equities research badysts have also recently commented on NTEC. Zacks Investment Research cut Intec Pharma from a “hold” rating to a “sell” rating in a research note on Wednesday, July 25th. Oppenheimer set a $15.00 target price on Intec Pharma and gave the company a “buy” rating in a research note on Wednesday, August 15th. Finally, HC Wainwright set a $16.00 target price on Intec Pharma and gave the company a “buy” rating in a research note on Thursday, August 16th. One research badyst has rated the stock with a hold rating and six have badigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $11.40.
Shares of NTEC traded up $0.38 on Friday, hitting $5.55. The company’s stock had a trading volume of 368,431 shares, compared to its average volume of 144,889. Intec Pharma has a fifty-two week low of $3.55 and a fifty-two week high of $8.55. The firm has a market capitalization of $168.07 million, a PE ratio of -3.36 and a beta of 0.98.
Intec Pharma (NASDAQ:NTEC) last released its earnings results on Wednesday, August 15th. The biotechnology company reported ($0.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.02). As a group, research badysts anticipate that Intec Pharma will post -1.36 EPS for the current fiscal year.
Several institutional investors have recently made changes to their positions in NTEC. Acuta Capital Partners LLC increased its holdings in shares of Intec Pharma by 8.7% during the 2nd quarter. Acuta Capital Partners LLC now owns 2,962,568 shares of the biotechnology company’s stock worth $13,035,000 after acquiring an additional 238,285 shares during the last quarter. Prosight Management LP acquired a new position in shares of Intec Pharma during the 2nd quarter worth approximately $4,951,000. DAFNA Capital Management LLC acquired a new position in shares of Intec Pharma during the 2nd quarter worth approximately $2,502,000. 683 Capital Management LLC acquired a new position in shares of Intec Pharma during the 2nd quarter worth approximately $660,000. Finally, Renaissance Technologies LLC increased its holdings in shares of Intec Pharma by 484.3% during the 2nd quarter. Renaissance Technologies LLC now owns 88,898 shares of the biotechnology company’s stock worth $391,000 after acquiring an additional 73,684 shares during the last quarter. Institutional investors own 45.09% of the company’s stock.
Intec Pharma Company Profile
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Featured Story: Outstanding Shares
Receive News & Ratings for Intec Pharma Daily – Enter your email address below to receive a concise daily summary of the latest news and badysts’ ratings for Intec Pharma and related companies with MarketBeat.com’s FREE daily email newsletter.
Source link
